Humacyte Opens First Human Heart-Bypass Vessel Study As Its Hospital Customer Base Expands

Symvess reached 49 hospital customers, and Humacyte expects fourth-quarter sales to at least double the third quarter’s.

Share
Humacyte Opens First Human Heart-Bypass Vessel Study As Its Hospital Customer Base Expands

Humacyte, which makes bioengineered blood vessels for surgical repair, began its first human heart-bypass vessel study by activating a clinical site in November. The company announced the milestone Tuesday in an SEC filing and accompanying release, alongside 151% sales growth for Symvess from the second quarter.

From Limb Repair To Heart Bypass

The FDA accepted Humacyte’s application to test its coronary tissue engineered vessel in people. Humacyte also completed a large-scale production lot for the early-stage heart-bypass study; enrollment of the first patients remains ahead, according to founder and CEO Laura Niklason.

The coronary vessel is investigational. Symvess, by contrast, won FDA approval in December 2024 for adults with severe limb-artery injuries who urgently need blood flow restored to avoid losing a limb and cannot receive a graft made from their own vein. Humacyte sells the product to hospitals and surgical care settings.

Dialysis access is the next proposed commercial use. Humacyte plans to seek FDA approval in November 2026, using results from three late-stage studies. Interim findings presented in October at ASN Kidney Week by Prabir Roy-Chaudhury of the University of North Carolina at Chapel Hill School of Medicine found that women receiving the vessel achieved usable access more than three months sooner than women receiving a fistula, the current standard, and spent more time without dialysis catheters during the first year.

Results from another late-stage dialysis study appeared in The Lancet Digital Health. That study observed better one-year outcomes with Humacyte’s vessel than with patients’ own fistulas, particularly among women and men with obesity and diabetes.

49 Hospitals And An October Boost

Symvess produced $1.0 million in third-quarter revenue, versus $0.4 million in the second quarter and $0.7 million a year earlier. Hospitals ordering it increased to 49 at September’s end from 34 at the end of June, a 44% increase.

October sales reached $0.8 million. Humacyte credited the growth to its revised commercial approach, introduced during the first half of 2026, and additional hospital customers. It anticipates adding at least 20 hospitals during the second half.

Jim Mercadante, Humacyte’s chief commercial officer, said, “we anticipate at least doubling our third quarter sales revenue in Q4 2026.”

Lower Cash Use, Costly Production

Humacyte reported $64.9 million in cash, cash equivalents and restricted cash at quarter-end. Operations consumed $15.0 million during the quarter, versus $23.9 million a year earlier, a reduction it attributed mainly to lower inventory production costs.

Research spending fell to $14.1 million from $17.3 million a year earlier and $18.1 million in the second quarter. Humacyte attributed the decline chiefly to fewer manufacturing runs for noncommercial work and winding down certain programs.

Production costs reached $1.4 million, versus $0.3 million a year earlier. Only $0.6 million related to units sold; the remaining $0.8 million consisted primarily of unused-capacity overhead and royalties.

The quarterly net loss narrowed to $15.5 million from $17.5 million, with $8.0 million in other net income coming mainly from noncash changes in liability values. Administrative spending rose to $9.0 million from $7.6 million, including $0.6 million in net expense tied to a litigation settlement reserve and legal costs.

Humacyte agreed to a $9 million settlement of a shareholder case alleging investors were misled about manufacturing quality and product safety.

Humacyte’s planned November dialysis application would seek a second approved use for its vessel; the heart-bypass program remains at the start of human testing.

Sources